Announcements Trials
Browse Landscape

Phase

Phase 3 9Phase 2 8Phase 1 4Phase 2/3 2Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioblastoma 5Neoplasms 3Recurrence 1Neuroectodermal Tumors 1Medulloblastoma 1Brain Neoplasms 1

Interventions

Temozolomide 26Bevacizumab 14Radiosurgery 12Radiotherapy 9pembrolizumab 8Carboplatin 8Trastuzumab 6temsirolimus 5Sirolimus 5Erlotinib Hydrochloride 5abemaciclib 4Paclitaxel 4Irinotecan 4Capecitabine 4tipifarnib 3Sorafenib 3Radiation 3Mental Status and Dementia Tests 3Ipilimumab 3Everolimus 3Aminolevulinic Acid 3130-nm albumin-bound paclitaxel 3tucatinib 2pertuzumab 2fludarabine 2durvalumab 2alovudine 2alectinib 2Vorinostat 2Surgical Procedures, Operative 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Brain Neoplasms × Lomustine × Clear all
NCT02765165 2021-07-23

Phase 1/2 Study of USL311 +/- Lomustine in Advanced Solid Tumors or Relapsed/Recurrent Glioblastoma Multiforme (GBM)

Proximagen, LLC

Phase 1/2 Terminated
26 enrolled 20 charts
CNS

Brain Neoplasms, Glioblastoma, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡